Salazar Resources closes $3.5 million non-brokered private placement at $0.35 per unit
Bitget2026/10/08 10:46Salazar Resources closed a non-brokered private placement raising gross proceeds of $3.5 million. Issued 10,000,000 units priced at $0.35 per unit. Each unit includes one common share, plus one-half warrant exercisable at $0.60 for two years. Insiders bought 405,000 units. Paid finder’s fees of $104,832.60 cash, plus 299,521 finder’s warrants exercisable at $0.35 for two years. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salazar Resources Limited published the original content used to generate this news brief via Newsfile (Ref. ID: 202610080645NEWSFILECNPR____20261008_318020_1) on October 08, 2026, and is solely responsible for the information contained therein.
- Salazar Resources closed a non-brokered private placement raising gross proceeds of $3.5 million.
- Issued 10,000,000 units priced at $0.35 per unit.
- Each unit includes one common share, plus one-half warrant exercisable at $0.60 for two years.
- Insiders bought 405,000 units.
- Paid finder’s fees of $104,832.60 cash, plus 299,521 finder’s warrants exercisable at $0.35 for two years.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
